Companies › Jacobio Pharmaceuticals
4 active drug programs in 7 registered trials: 6 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JAB-8263 | – | Phase 2 | Rheumatoid Arthritis (RA); NSCLC | Jun 2027 |
| JAB-23E73 Pan-KRAS inhibitor | KRAS | Phase 1 | Advanced Solid Tumor; Advanced Solid Tumors; Metastatic Pancreatic Ductal Adenocarcinoma | Dec 2026 |
| JAB-30355 TP53 Y220C mutant-selective stabilizer | TP53 | Phase 1 | Solid Tumors | Jan 2027 |
| JAB-2485 Aurora A inhibitor | AURKA | Phase 1 | Solid Tumors | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06959615 | JAB-23E73 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT06386146 | JAB-30355 | Phase 1 | Solid Tumors | Oncology | Jan 2027 |
| NCT07684157 | JAB-8263 | Phase 2 | Rheumatoid Arthritis (RA) | Immunology | Jun 2027 |
| NCT05490472 | JAB-2485 | Phase 1 | Solid Tumors | Oncology | Aug 2027 |
| NCT04686682 | JAB-8263 | Phase 1 | NSCLC | Oncology | Jan 2028 |
| NCT06973564 | JAB-23E73 | Phase 1 | Advanced Solid Tumors | Oncology | Nov 2028 |
| NCT07640295 | JAB-23E73 | Phase 1 | Metastatic Pancreatic Ductal Adenocarcinoma | Oncology | Dec 2029 |
Kumquat Biosciences Ranok Therapeutics (Hangzhou) Genfleet Therapeutics (Shanghai) Multitude Therapeutics Abbisko Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.